## HEAD AND NECK ONCOLOGY

Sandro J. Stoeckli · Moreno Guidicelli Andreas Schneider · Alexander Huber **Stephan Schmid** 

# Quality of life after treatment for early laryngeal carcinoma

Introduction

Received: 7 September 2000 / Accepted: 6 November 2000

Abstract Radiotherapy and surgery for early laryngeal cancer achieve comparably good results in patient survival, and the choice of treatment between them is being influenced increasingly by the expected voice quality and quality of life (QoL). The superiority of vocal function after radiotherapy has been shown in previous objective voice assessment studies. This study compared the QoL of long-term survivors after endoscopic laser surgery or radiotherapy for early laryngeal carcinoma. QoL was evaluated with two validated questionnaires: the global EORTC QLQ-C30 and the head- and neck-specific EORTC QLQ-H&N35. A total of 62 patients were included. Among 56 patients completing the questionnaires (90% completion rate) 40 were treated by endoscopic CO<sub>2</sub> laser surgery and 16 with radiation therapy. All 56 patients showed a good global QoL with no significant difference between the two treatment modalities. The headand neck-specific evaluation revealed significantly better scores for surgically treated patients in questions about swallowing of solid food, xerostomia, and tooth problems, but no difference in questions about voice quality. Both treatment modalities achieve good QoL after treatment of early laryngeal tumors. Irradiated patients mainly complain about xerostomia related problems. In contrast to objective measurements long-term survivors after surgery do not rate their voice poorer than irradiated patients. The EORTC questionnaires are validated and useful tools in assessing QoL and should further be used in prospective trials.

**Keywords** Quality of life · Laryngeal · Carcinoma

S. J. Stoeckli ( ) · M. Guidicelli · A. Schneider · A. Huber S. Schmid

Clinic of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich,

Frauenklinikstrasse 24, 8091 Zurich, Switzerland e-mail: stoeckli@orl.usz.ch,

Tel.: +41-1-2555869, Fax: +41-1-2554556

# **Patients and methods**

uated and validated [2, 3].

We retrospectively reviewed the charts of 96 patients treated with a curative intent for an early (T1 and T2) squamous cell carcinoma of the larynx at the Clinic of Otorhinolaryngology, Head

term survivors after treatment of early laryngeal squamous cell carcinomas using the EORTC questionnaires endoscopic laser surgery or radiotherapy.

The aim of our study was to analyze the QoL of longand to compare the results of patients treated with either

The gold standard for the evaluation of the success of a

specific cancer treatment is survival analysis. Because

treatment of head and neck carcinoma has great impact on

important basic functions of daily life such as breathing,

verbal communication, and swallowing, not only mere

survival but also the survivors' quality of life (QoL) must

be addressed as an endpoint of therapy evaluation [7, 14].

Assessment of QoL has proven difficult due to different

existing definitions of QoL and varying quality of evalua-

tion instruments [8, 12]. In recent years research on QoL

questionnaires has revealed that QoL evaluation must be

multidimensional and performed by patient's self-assess-

ment [13]. For this purpose several QoL questionnaires

have been developed and validated. The European Orga-

nization for Research and Treatment of Cancer (EORTC)

released an integrated system for assessment of the

health-related QoL of cancer patients. The general

EORTC Quality of Life questionnaire core 30 (EORTC

QLQ-C30) incorporates five functional scales (physical,

role, cognitive, emotional, and social), three symptom

scales (fatigue, pain, and nausea and vomiting), a global

health status, and a number of single items assessing ad-

ditional symptoms [1]. The core questionnaire has been

supplemented by the head- and neck-specific module

EORTC QLQ-H&N35. Both the core questionnaire and

the head and neck module have continuously been reeval-

and Neck Surgery, of the University Hospital in Zurich, Switzerland, between January 1990 and December 1995. Ten patients were lost to follow-up. In January 1999 a total of 62 patients were still alive, free of tumor and accessible for the study. The patients were divided into two groups based on the treatment modality, either endoscopic laser surgery (n = 40) or radiotherapy (n = 16).

The EORTC questionnaires QLQ-C30 and QLQ-H&N35 were mailed to a total of 62 patients together with a letter of introduction. Nonresponding patients received one follow-up request and were contacted by phone. Of these, 56 (90%) returned finally responded. The general EORTC QLQ-C30 consists of 30 questions and incorporates five functional domains (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea/vomiting), a global health status, and a number of single items assessing additional symptoms. The core questionnaire has been supplemented by the head and neck specific module EORTC QLQ-H&N35 consisting of 35 further questions divided into seven multiple-item symptom scales assessing pain, swallowing, senses (taste and smell), speech, social eating, social contact and sexuality and six symptom items (teeth problems, trismus, dry mouth, sticky saliva, cough, and feeling ill). For scoring the principles proposed in the EORTC Scoring Manual [6] were strictly followed. All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high (healthy) level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptoms or problems.

Statistical analysis was performed using t test for comparison of means of large groups and Student's t test for comparison of means of small groups.

### **Results**

The general EORTC QLQ-C30 revealed a good level of QoL in all patients of both treatment groups. The mean functional domains were between 80% and 90% and the mean global health status was 71.9 and 73.9%, respectively. No statistically significant differences were found

 Table 1
 EORTC QLQ-C30: radiotherapy versus surgery in early laryngeal carcinomas

EORTC QLQ C-30	Surgery	Radiotherapy	P
Functional scales			
Physical	$89.8 \pm 16.3$	$83.1 \pm 22.4$	n.s.
Role	$85.8 \pm 27.1$	$82.3 \pm 27.5$	n.s.
Emotional	$80.8 \pm 22.1$	$85.6 \pm 16.2$	n.s.
Cognitive	$86.7 \pm 18.6$	$86.5 \pm 19.5$	n.s.
Social	$85.0 \pm 25.8$	$84.4 \pm 20.4$	n.s.
Global health status	$71.9 \pm 24.6$	$73.9 \pm 21.8$	n.s.
Symptom scales/items			
Fatigue	$20.5 \pm 27.2$	$25.7 \pm 25.2$	n.s.
Nausea and vomiting	$3.8 \pm 12.8$	$4.4 \pm 13.3$	n.s.
Pain	$8.3 \pm 21.4$	$22.2 \pm 31.9$	n.s.
Dyspnea	$15.8 \pm 25.0$	$15.6 \pm 30.5$	n.s.
Insomnia	$12.5 \pm 23.5$	$31.3 \pm 37.5$	n.s.
Appetite loss	$5.0 \pm 16.1$	$17.8 \pm 30.5$	n.s.
Constipation	$5.8 \pm 16.7$	$11.1 \pm 30.0$	n.s.
Diarrhea	$5.8 \pm 19.8$	$8.9 \pm 19.8$	n.s.
Financial difficulties	$19.2\pm30.1$	$4.8 \pm 17.8$	< 0.05

in any of the domains and symptom scales between the two treatment modalities, with the exception of significantly fewer financial difficulties in the radiation therapy group (Table 1). The evaluation by the head- and neck-specific module EORTC QLQ-H&N35 showed low symptom scales for most items. Only speech related and some eating related symptoms were evaluated as trouble-some in both groups. Significantly better scores for the surgically treated patients were found in the single items swallowing solid food, dry mouth, and tooth problems. All other symptoms, including hoarseness, were judged equally by the two treatment groups (Table 2).

### **Discussion**

Irrespective of the treatment modality – radiotherapy or surgery – the global QoL was considered as good, with a mean global health status in both groups around 70%. Functional domains such as physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning revealed nearly normal mean scores between 83% and 96% after both treatment regimens. These results are in good agreement with previous reports in the literature [9, 10, 16]. The surgically treated patients complained significantly more of financial difficulties. The reason for this is unclear and probably not relevant. The financial situation was not a factor influencing the choice of treatment modality.

The evaluation by the head-and neck-specific questionnaire H&N35 yielded low symptom scores for most items in all patients, indicating that long-term survivors do not suffer anymore from tumor- or treatment-related symptoms. As expected, the items asking for speech- and eating-related symptoms showed elevated scores after treatment in both groups. Both radiotherapy and surgery adversely affected the ability to talk, but there was no statistically significant difference between the two modalities. Patients treated by endolaryngeal laser surgery did not rate their voice as poorer than those after radiotherapy. This stands in contrast with most objective voice evaluations comparing these treatment modalities [5, 11, 15, 17]. The negative impact of radiotherapy on the ability of swallowing solid food and xerostomia was significant. These xerostomia related long-term effects of radiation are often underestimated, but, as shown in our study, have substantially more detrimental effect on QoL than voice function, which is generally considered to be more important.

From our findings we can conclude that for the treatment of early laryngeal cancer endoscopic laser surgery and radiotherapy achieve comparably good results regarding QoL. The QoL should be routinely and prospectively assessed in all cancer patients as an endpoint of therapy evaluation. For this purpose the questionnaires proposed by the EORTC have proved to be very useful.

**Table 2** EORTC QLQ H&N35: radiotherapy versus surgery in early laryngeal carcinomas

EORTC QLQ H&N35	Surgery	Radiotherapy	P
Pain	$7.7 \pm 21.3$	$13.5 \pm 29.3$	n.s.
Pain in the mouth	$4.2 \pm 13.5$	$8.9 \pm 19.8$	n.s.
Pain in the jaw	$2.5 \pm 8.9$	$2.2 \pm 8.6$	n.s.
Soreness in the mouth	$5.8 \pm 14.9$	$4.4 \pm 11.7$	n.s.
Painful throat	$10.8 \pm 20.5$	$20.8 \pm 29.5$	n.s.
Use of pain killers	$15.0 \pm 36.2$	$31.3 \pm 47.9$	n.s.
Swallowing	$6.0 \pm 17.9$	$12.7 \pm 26.5$	n.s.
Problems with liquids	$6.7 \pm 20.3$	$11.9 \pm 28.1$	n.s.
Problems swallowing purreed food	$0.8 \pm 5.3$	$9.5 \pm 27.5$	n.s.
Problems swallowing solid food	$5.0 \pm 16.1$	$24.4 \pm 32.0$	< 0.05
Choked when swallowing	$11.7 \pm 23.3$	$4.8 \pm 12.1$	n.s.
Social eating	$10.2 \pm 24.0$	$23.4 \pm 34.8$	n.s.
Trouble eating	$5.8 \pm 18.3$	$20.0 \pm 32.9$	n.s.
Trouble eating in front of family	$2.5 \pm 11.7$	$6.7 \pm 18.7$	n.s.
Trouble eating in front of other persons	$5.0 \pm 19.3$	$15.6 \pm 33.0$	n.s.
Trouble enjoying meals	$5.0 \pm 16.1$	$13.3 \pm 27.6$	n.s.
Dry mouth	$30.0 \pm 32.8$	$56.3 \pm 39.8$	< 0.05
Sticky saliva	$19.2 \pm 32.8$	$40.0 \pm 40.2$	n.s.
Problems with teeth	$8.3 \pm 21.0$	$28.9 \pm 33.0$	< 0.05
Problems opening the mouth wide	$5.8 \pm 19.8$	$6.7 \pm 18.7$	n.s.
Senses	$9.9 \pm 23.7$	$19.4 \pm 35.3$	n.s.
Problems with sense of smell	$8.3 \pm 18.1$	$24.4 \pm 38.8$	n.s.
Problems with sense of taste	$5.0 \pm 14.2$	$19.0 \pm 38.6$	n.s.
Feeling ill	$13.3 \pm 21.1$	$26.2 \pm 32.5$	n.s.
Use of nutritional supplements	$2.5 \pm 15.8$	$7.1 \pm 26.7$	n.s.
Use of feeding tube	$0.0 \pm 0.0$	$0.0 \pm 0.0$	n.s.
Weight loss	$5.0 \pm 22.1$	$28.6 \pm 46.9$	n.s.
Weight gain	$17.5 \pm 38.5$	$14.3 \pm 36.3$	n.s.
Coughing	$27.5 \pm 28.1$	$35.4 \pm 35.4$	n.s.
Speech	$32.8 \pm 34.8$	$21.4 \pm 33.9$	n.s.
Hoarseness	$41.7 \pm 32.7$	$37.5 \pm 34.2$	n.s.
Trouble talking to other persons	$30.8 \pm 34.9$	$13.3 \pm 30.3$	n.s.
Trouble talking on the phone	$25.8 \pm 35.8$	$13.3 \pm 32.9$	n.s.
Social contact	$5.0 \pm 16.2$	$8.0 \pm 25.0$	n.s.
Bothered by appearance	$5.0 \pm 16.1$	$11.1 \pm 30.0$	n.s.
Trouble having physical contact	$6.7 \pm 20.3$	$6.7 \pm 18.7$	n.s.
With family	$7.5 \pm 22.0$	$6.7 \pm 25.8$	n.s.
With friends	$10.8 \pm 24.3$	$6.7 \pm 25.8$	n.s.
Trouble going out in public	$11.7 \pm 23.3$	$8.9 \pm 26.6$	n.s.
Sexuality	$25.6 \pm 33.5$	$31.1 \pm 38.1$	n.s.
Less interest in sex	$24.8 \pm 33.1$	$31.1 \pm 36.7$	n.s.
Less sexual enjoyment	$26.5 \pm 34.3$	$31.1 \pm 40.8$	n.s.

**Acknowledgements** The paper was presented at the Third Congress of the European Laryngological Society, 2000, Paris, France.

## References

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

- 2. Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen AB, Razavi D, Maher EJ, Kaasa S (1994) Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 33:879–885
- 3. Bjordal K, Kaasa S (1992) Psychometric validation of the EORTC core quality of life questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncologica 31:311–321
- 4. Bjordal K, Kaasa S, Mastekaasa A (1994) Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 28:847–856

- Elner A, Fex S (1988) Carbon dioxide laser as a primary treatment of glottic T1S and T1A tumours. Acta Otolaryngol Suppl 449:135–139
- 6. Fayers PM, Aaronson NK, Bjordal K, Curran D, Groenvold M (1999) The EORTC QLQ-C30 Scoring manual, 2nd edn. European Organization for Research and Treatment of Cancer, Brussels
- 7. Furst CJ (1996) Radiotherapy for cancer. Quality of life. Acta Oncol 35 [Suppl 7]:141–138
- 8. Gotay CC, Moore TD (1992) Assessing quality of life in head and neck cancer. Qual Life Res 1:5–17
- Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Jannert M, Kaasa S, Sullivan M, Westin T (1997) Prospective, longitudinal quality-of-life Study of patients with head and neck cancer: a feasibility study including the EORTC QLQ-C30. Otolaryngol Head Neck Surg 116:666–673
- Hammerlid E, Mercke C, Sullivan M, Westin T (1998) A prospective quality of life study of patients with laryngeal carcinoma by tumor stage and different radiation therapy schedules. Laryngoscope 108:747–759
- 11. Hillman RE, Walsh MJ, Fisher SG, Wolf GT, Hong WK (1998) Functional outcomes following treatment for advanced laryngeal cancer. I. Voice preservation in advanced laryngeal cancer. II. Laryngectomy rehabilitation: the state of the art in the VA system. Ann Otol Rhinol Laryngol 107:2–27

- Morton RP, Witterick IJ (1995) rationale and development of a quality-of-life instrument for head-and-neck cancer patients. Am J Otolaryngol 16:284–293
- 13. Otto RA, Lawrence V, Dobie RA, Sakai C (1997) Impact of a laryngectomy on quality of life: Perspective of the patient versus that of the health care provider. Ann Otol Rhinol Laryngol 106:693–699
- 14. Rodary C, Leplège A, Hill C (1998) Évaluation de la qualité de vie dans la recherche clinique en cancérologie. Bull Cancer 85:140–148
- 15. Stewart MG, Chen AY, Stach CB (1998) Outcomes analysis of voice and quality of life in patients with laryngeal cancer. Arch Otolaryngol Head Neck Surg 124:143–148
- 16. Succo G, Bramardi F, Airoldi M, Gabriele P, Riva F, Moletto M, Rosso S, Caiazzo A, Sartoris A (1997) La qualità della vita post-trattamento nei pazienti affetti da carcinoma laringeo. Acta Otorhinolaryngol Ital 17:32–44
- 17. Verdonck-de Leeuw IM, Hilgers F, Keus RB, Koopmans-van Beinum FJ, Greven AJ, de Jong J, Vreeburg G, Bartelink H (1999) Multidimensional assessment of voice characteristics after radiotherapy for early glottic cancer. Laryngoscope 109: 241–248